Trimedyne (OTC:TMED) Reports Quarterly Revenue of $1.7M

Trimedyne (OTC:TMED) today reported its financial results for the quarter ended December 31, 2010. As I write, shares of the company were not trading but the last recorded price was $0.131 per share on February 18, 2011. Trimedyne has an average daily volume of just over 20,000 shares; a market cap of $2.4 million; and a 52-week range between $0.05 and $0.60 per share.

Revenues for the quarter were $1,635,000, a 1.1% decrease from revenues of $1,654,000 for the prior year's quarter. The Company had a net loss of ($293,000) or ($0.02) per share for the current quarter, compared to a loss of ($300,000) or ($0.02) per share for the same quarter of the prior year.

Marvin P. Loeb, Sc.D., CEO & Chairman of Trimedyne, said, "We regret not being able to report a lower loss for the current Quarter."

Dr. Loeb continued, "The Company recently introduced a line of 200, 365, 550 and 1000 micron Single Use optical fibers, for use with our Holmium Lasers and Holmium Lasers with a compatible connector made by others, for the fragmentation of urinary stones in the kidney, ureter or bladder, biliary stones in the gall bladder and for other applications in surgery. In the United States and other developed countries, many hospitals and surgery centers want the convenience and safety of using a new optical fiber, with a factory polished tip and confirmed sterility for each case, rather than depending on their busy nurses to clean, clip and re-sterilize Reusable optical fibers.

"These new Single Use Optical Fibers and our new VaporMAX Side Firing Fibers enable us to better serve our customers in the U.S. and other developed countries, while we continue to sell Reusable Optical Fibers in other countries where cost is a major concern."

Trimedyne manufactures proprietary Holmium lasers and patented fiber optic laser devices for vaporizing the prostate to treat BPH, vaporizing spinal disc tissue to treat herniated or ruptured discs and in a variety of other, minimally invasive procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery.

For more information, please visit Trimedyne's website, http://www.trimedyne.com.

Distributed by IntelBuilder Social Media Platform